The evolving field of personalised medicine is playing an increasingly important role in
cancer prevention, diagnosis, prognosis and therapeutics. Its importance in clinical …

Triple-negative breast cancers (TNBCs) constitute a heterogeneous subtype of breast
cancers that have a poor clinical outcome. Although no approved targeted therapy is …

Determination of pharmaceuticals especially anticancer drugs is one of the important issues
in environmental and medical investigation and creating good information about human …

Mainstream cancer research has long been focused on the biology of the cancer cell. This
approach was logical, as these defective cells harbor the genetic mutations at the root of …

Our understanding of breast cancer and its therapeutic approach has improved greatly due
to the advancement of molecular biology in recent years. Clinically, breast cancers are …

Constitutive JAK-STAT pathway activation occurs in most myeloproliferative neoplasms as
well as in a significant proportion of other hematologic malignancies, and is frequently a …

With half of the world's population at risk for malaria infection and with drug resistance on the
rise, the search for mutation-resistant therapies has intensified. We report here a therapy for …

The initial treatment for chronic myeloid leukemia in chronic phase (CP‐CML) represents a
complex process, which includes a prompt and precise diagnosis, the choice among three …

Mutations in ACTA2, encoding the smooth muscle cell (SMC)-specific isoform of α-actin (α-
SMA), cause thoracic aortic aneurysms and dissections and occlusive vascular diseases …

Imatinib mesylate (IM) is the first developed protein kinase inhibitor and recently it has
topped consumption rates among targeted and total anticancer drugs. Although there are …